Myovant Sciences Ltd

NYSE:MYOV   3:59:54 PM EDT
+0.16 (+0.68%)

Myovant Sciences And Pfizer Announce FDA Acceptance Of Supplemental New Drug Application For Myfembree For Management Of Moderate To Severe Pain Associated With Endometriosis

Published: 09/09/2021 12:21 GMT
Myovant Sciences Ltd (MYOV) - Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for Myfembree® for the Management of Moderate to Severe Pain Associated With Endometriosis.
Myovant Sciences Ltd - FDA Set a Target Action Date of May 6, 2022 for This Snda Under Prescription Drug User Fee Act.